Please check your internet connection and try again.
# Hyaluronic Acid
## Overview
Hyaluronic acid (HA) is a naturally occurring high-molecular-weight glycosaminoglycan found in connective tissue, synovial fluid, and the extracellular matrix. Therapeutic forms include intra-articular injections (viscosupplementation) for osteoarthritis and topical formulations for wound healing or dermatological aesthetics.
## Primary Indications
* **Ophthalmology:** Surgical aid in cataract extraction, IOL implantation, and corneal surgery.
* **Rheumatology (Intra-articular):** Treatment of pain in osteoarthritis (OA) of the knee in patients who have failed conservative non-pharmacologic therapy and simple analgesics.
* **Dermatology/Wound Care:** Topical management of cutaneous ulcers, wounds, or cosmetic volume enhancement (dermal fillers).
## Adult Dosing
* **Osteoarthritis (Knee):** Dosing varies by specific product (e.g., Hyalgan, Synvisc, Euflexxa).
* *Hyalgan:* 20 mg (2 mL) intra-articular injection once weekly for 5 weeks.
* *Synvisc-One:* 48 mg (6 mL) intra-articular injection as a single dose.
* *Euflexxa:* 20 mg (2 mL) intra-articular injection once weekly for 3 weeks.
* **Ophthalmic/Topical:** Use per specific product labeling according to the procedure or condition.
## Pediatric Dosing
* **Safety/Efficacy:** Not established for routine use in pediatric patients. Use is generally restricted to specialized ophthalmologic surgical cases or specific off-label wound care protocols as determined by institutional pediatric standards.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No dose adjustments typically required for localized formulations (intra-articular/topical/ophthalmic) as systemic absorption is negligible.
* **Elderly:** No routine dose adjustments required.
## Contraindications
* Known hypersensitivity to hyaluronan preparations.
* Known hypersensitivity to avian (bird) proteins (for products derived from avian sources).
* Active joint infection or skin inflammation/infection in the area of the injection site.
## Adverse Effects
* **Injection Site:** *Most common:* Joint pain, swelling, stiffness, or effusion. These are usually transient.
* **Systemic:** Rarely, hypersensitivity reactions including anaphylaxis or pseudo-sepsis (acute inflammatory response).
* **General:** Arthralgia, back pain, and injection site pruritus.
## Key Drug Interactions
* **Disinfectants:** Do not use skin disinfectants containing quaternary ammonium salts (e.g., benzalkonium chloride) for cleaning the injection site prior to intra-articular administration, as HA can precipitate.
* **Local Anesthetics:** Generally compatible, but ensure sterile technique is maintained during co-administration.
## Monitoring
* **Efficacy:** Reduction in joint pain scores and improvement in functional mobility (WOMAC index).
* **Safety:** Monitor for signs of localized infection (increased heat, erythema, extreme tenderness) or systemic inflammatory response (fever, chills) post-injection.
## Clinical Pearls
* **Viscosupplementation:** Efficacy is modest and highly dependent on patient selection. If no improvement is seen after one full course, repeating the injection series is typically not recommended.
* **Storage:** Most intra-articular products should be stored at room temperature (or refrigerated, depending on the manufacturer); do not freeze.
* **Differentiation:** Ensure the formulation is intended for the specific route (e.g., do not use injectable fillers for intra-articular use).
***
*Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Dosing and administration protocols vary by product brand and local institutional guidelines. Always verify current prescribing information, package inserts, and clinical protocols prior to administration.*
